Biocryst Pharmaceuticals (BCRX) Change in Accured Expenses (2010 - 2022)

Biocryst Pharmaceuticals has reported Change in Accured Expenses for 13 years, with the latest figure at -$6.3 million in Q4 2022.

• For the quarter ending Q4 2022, Change in Accured Expenses fell 2334.15% year-over-year to -$6.3 million; the trailing twelve-month figure through Sep 2022 stood at $6.6 million (up 6.06% YoY), and the FY2021 full-year result was $4.2 million, down 38.4% from the prior year.
• Change in Accured Expenses for Q4 2022 stood at -$6.3 million, down from $6.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $6.3 million in Q3 2022, with the low at -$6.3 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged $763500.0 across 5 years, with a median of $1.4 million in 2018.
• The largest YoY upside for Change in Accured Expenses was 1782.79% in 2022 against a maximum downside of 2334.15% in 2022.
• Biocryst Pharmaceuticals' Change in Accured Expenses stood at $1.4 million in 2018, then increased by 4.22% to $1.5 million in 2019, then surged by 59.76% to $2.4 million in 2020, then slumped by 88.0% to $284000.0 in 2021, then plunged by 2334.15% to -$6.3 million in 2022.
• The last three Change in Accured Expenses figures came in at -$6.3 million (Q4 2022), $6.3 million (Q3 2022), and $284000.0 (Q4 2021), per Business Quant data.